Medical Care
Global Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Market Research Report 2025
- Mar 11, 25
- ID: 74281
- Pages: 111
- Figures: 117
- Views: 31
The global market for Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics was valued at US$ million in the year 2024 and is projected to reach a revised size of US$ million by 2031, growing at a CAGR of %during the forecast period.
Co-development partnering allow the parties to securitize value and reduce risk, but keep a part of the potential upside should the product reach the market. Event if the licensor does not commercialize the project they can either sell those rights to the licensee partner or another partner for an amount higher than would have been achieved at an earlier stage licensing deal.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
This report aims to provide a comprehensive presentation of the global market for Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics.
The Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
1ST Biotherapeutics
3B Pharmaceuticals
3D-Micromac
3DMed
3D Systems
10X Genomics
A*STAR Agency for Science
Technology and Research
A*STAR Institute of Microelectronics (IME)
A2A Pharmaceuticals
Abbvie
AbCellera
ABL Bio
Abpro
Academy of Military Medical Sciences (China)
Accellix
Accord Healthcare
AccuGenomics
ACEA Biosciences
AC Immune
Acoustic MedSystems
Adaptimmune
Aduro BioTech
Advaxis
Adventus Ventures
Aerolase
Segment by Type
Asset purchase
Assignment
Co-development
Co-market
Co-promotion
Collaborative R&D
Contract service
CRADA
Cross-licensing
Others
Segment by Application
Industry sector
Therapy areas
Technology type
Deal components
Financial terms
Stage of development
Others
By Region
North America
United States
Canada
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Rest of Europe
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
Co-development partnering allow the parties to securitize value and reduce risk, but keep a part of the potential upside should the product reach the market. Event if the licensor does not commercialize the project they can either sell those rights to the licensee partner or another partner for an amount higher than would have been achieved at an earlier stage licensing deal.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
This report aims to provide a comprehensive presentation of the global market for Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics.
The Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
1ST Biotherapeutics
3B Pharmaceuticals
3D-Micromac
3DMed
3D Systems
10X Genomics
A*STAR Agency for Science
Technology and Research
A*STAR Institute of Microelectronics (IME)
A2A Pharmaceuticals
Abbvie
AbCellera
ABL Bio
Abpro
Academy of Military Medical Sciences (China)
Accellix
Accord Healthcare
AccuGenomics
ACEA Biosciences
AC Immune
Acoustic MedSystems
Adaptimmune
Aduro BioTech
Advaxis
Adventus Ventures
Aerolase
Segment by Type
Asset purchase
Assignment
Co-development
Co-market
Co-promotion
Collaborative R&D
Contract service
CRADA
Cross-licensing
Others
Segment by Application
Industry sector
Therapy areas
Technology type
Deal components
Financial terms
Stage of development
Others
By Region
North America
United States
Canada
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Rest of Europe
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Market Size Growth Rate by Type: 2020 VS 2024 VS 2031
1.2.2 Asset purchase
1.2.3 Assignment
1.2.4 Co-development
1.2.5 Co-market
1.2.6 Co-promotion
1.2.7 Collaborative R&D
1.2.8 Contract service
1.2.9 CRADA
1.2.10 Cross-licensing
1.3 Market by Application
1.3.1 Global Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Market Growth by Application: 2020 VS 2024 VS 2031
1.3.2 Industry sector
1.3.3 Therapy areas
1.3.4 Technology type
1.3.5 Deal components
1.3.6 Financial terms
1.3.7 Stage of development
1.3.8 Others
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Global Growth Trends
2.1 Global Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Market Perspective (2020-2031)
2.2 Global Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Growth Trends by Region
2.2.1 Global Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Market Size by Region: 2020 VS 2024 VS 2031
2.2.2 Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Historic Market Size by Region (2020-2025)
2.2.3 Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Forecasted Market Size by Region (2026-2031)
2.3 Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Market Dynamics
2.3.1 Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Industry Trends
2.3.2 Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Market Drivers
2.3.3 Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Market Challenges
2.3.4 Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Players by Revenue
3.1.1 Global Top Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Players by Revenue (2020-2025)
3.1.2 Global Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Revenue Market Share by Players (2020-2025)
3.2 Global Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Global Key Players Ranking by Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Revenue
3.4 Global Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Market Concentration Ratio
3.4.1 Global Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Revenue in 2024
3.5 Global Key Players of Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Head office and Area Served
3.6 Global Key Players of Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics, Product and Application
3.7 Global Key Players of Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics, Date of Enter into This Industry
3.8 Mergers & Acquisitions, Expansion Plans
4 Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Breakdown Data by Type
4.1 Global Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Historic Market Size by Type (2020-2025)
4.2 Global Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Forecasted Market Size by Type (2026-2031)
5 Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Breakdown Data by Application
5.1 Global Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Historic Market Size by Application (2020-2025)
5.2 Global Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Forecasted Market Size by Application (2026-2031)
6 North America
6.1 North America Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Market Size (2020-2031)
6.2 North America Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Market Growth Rate by Country: 2020 VS 2024 VS 2031
6.3 North America Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Market Size by Country (2020-2025)
6.4 North America Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Market Size by Country (2026-2031)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Market Size (2020-2031)
7.2 Europe Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Market Growth Rate by Country: 2020 VS 2024 VS 2031
7.3 Europe Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Market Size by Country (2020-2025)
7.4 Europe Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Market Size by Country (2026-2031)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Market Size (2020-2031)
8.2 Asia-Pacific Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Market Growth Rate by Region: 2020 VS 2024 VS 2031
8.3 Asia-Pacific Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Market Size by Region (2020-2025)
8.4 Asia-Pacific Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Market Size by Region (2026-2031)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Market Size (2020-2031)
9.2 Latin America Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Market Growth Rate by Country: 2020 VS 2024 VS 2031
9.3 Latin America Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Market Size by Country (2020-2025)
9.4 Latin America Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Market Size by Country (2026-2031)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Market Size (2020-2031)
10.2 Middle East & Africa Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Market Growth Rate by Country: 2020 VS 2024 VS 2031
10.3 Middle East & Africa Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Market Size by Country (2020-2025)
10.4 Middle East & Africa Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Market Size by Country (2026-2031)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 1ST Biotherapeutics
11.1.1 1ST Biotherapeutics Company Details
11.1.2 1ST Biotherapeutics Business Overview
11.1.3 1ST Biotherapeutics Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Introduction
11.1.4 1ST Biotherapeutics Revenue in Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Business (2020-2025)
11.1.5 1ST Biotherapeutics Recent Development
11.2 3B Pharmaceuticals
11.2.1 3B Pharmaceuticals Company Details
11.2.2 3B Pharmaceuticals Business Overview
11.2.3 3B Pharmaceuticals Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Introduction
11.2.4 3B Pharmaceuticals Revenue in Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Business (2020-2025)
11.2.5 3B Pharmaceuticals Recent Development
11.3 3D-Micromac
11.3.1 3D-Micromac Company Details
11.3.2 3D-Micromac Business Overview
11.3.3 3D-Micromac Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Introduction
11.3.4 3D-Micromac Revenue in Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Business (2020-2025)
11.3.5 3D-Micromac Recent Development
11.4 3DMed
11.4.1 3DMed Company Details
11.4.2 3DMed Business Overview
11.4.3 3DMed Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Introduction
11.4.4 3DMed Revenue in Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Business (2020-2025)
11.4.5 3DMed Recent Development
11.5 3D Systems
11.5.1 3D Systems Company Details
11.5.2 3D Systems Business Overview
11.5.3 3D Systems Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Introduction
11.5.4 3D Systems Revenue in Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Business (2020-2025)
11.5.5 3D Systems Recent Development
11.6 10X Genomics
11.6.1 10X Genomics Company Details
11.6.2 10X Genomics Business Overview
11.6.3 10X Genomics Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Introduction
11.6.4 10X Genomics Revenue in Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Business (2020-2025)
11.6.5 10X Genomics Recent Development
11.7 A*STAR Agency for Science
11.7.1 A*STAR Agency for Science Company Details
11.7.2 A*STAR Agency for Science Business Overview
11.7.3 A*STAR Agency for Science Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Introduction
11.7.4 A*STAR Agency for Science Revenue in Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Business (2020-2025)
11.7.5 A*STAR Agency for Science Recent Development
11.8 Technology and Research
11.8.1 Technology and Research Company Details
11.8.2 Technology and Research Business Overview
11.8.3 Technology and Research Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Introduction
11.8.4 Technology and Research Revenue in Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Business (2020-2025)
11.8.5 Technology and Research Recent Development
11.9 A*STAR Institute of Microelectronics (IME)
11.9.1 A*STAR Institute of Microelectronics (IME) Company Details
11.9.2 A*STAR Institute of Microelectronics (IME) Business Overview
11.9.3 A*STAR Institute of Microelectronics (IME) Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Introduction
11.9.4 A*STAR Institute of Microelectronics (IME) Revenue in Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Business (2020-2025)
11.9.5 A*STAR Institute of Microelectronics (IME) Recent Development
11.10 A2A Pharmaceuticals
11.10.1 A2A Pharmaceuticals Company Details
11.10.2 A2A Pharmaceuticals Business Overview
11.10.3 A2A Pharmaceuticals Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Introduction
11.10.4 A2A Pharmaceuticals Revenue in Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Business (2020-2025)
11.10.5 A2A Pharmaceuticals Recent Development
11.11 Abbvie
11.11.1 Abbvie Company Details
11.11.2 Abbvie Business Overview
11.11.3 Abbvie Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Introduction
11.11.4 Abbvie Revenue in Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Business (2020-2025)
11.11.5 Abbvie Recent Development
11.12 AbCellera
11.12.1 AbCellera Company Details
11.12.2 AbCellera Business Overview
11.12.3 AbCellera Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Introduction
11.12.4 AbCellera Revenue in Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Business (2020-2025)
11.12.5 AbCellera Recent Development
11.13 ABL Bio
11.13.1 ABL Bio Company Details
11.13.2 ABL Bio Business Overview
11.13.3 ABL Bio Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Introduction
11.13.4 ABL Bio Revenue in Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Business (2020-2025)
11.13.5 ABL Bio Recent Development
11.14 Abpro
11.14.1 Abpro Company Details
11.14.2 Abpro Business Overview
11.14.3 Abpro Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Introduction
11.14.4 Abpro Revenue in Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Business (2020-2025)
11.14.5 Abpro Recent Development
11.15 Academy of Military Medical Sciences (China)
11.15.1 Academy of Military Medical Sciences (China) Company Details
11.15.2 Academy of Military Medical Sciences (China) Business Overview
11.15.3 Academy of Military Medical Sciences (China) Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Introduction
11.15.4 Academy of Military Medical Sciences (China) Revenue in Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Business (2020-2025)
11.15.5 Academy of Military Medical Sciences (China) Recent Development
11.16 Accellix
11.16.1 Accellix Company Details
11.16.2 Accellix Business Overview
11.16.3 Accellix Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Introduction
11.16.4 Accellix Revenue in Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Business (2020-2025)
11.16.5 Accellix Recent Development
11.17 Accord Healthcare
11.17.1 Accord Healthcare Company Details
11.17.2 Accord Healthcare Business Overview
11.17.3 Accord Healthcare Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Introduction
11.17.4 Accord Healthcare Revenue in Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Business (2020-2025)
11.17.5 Accord Healthcare Recent Development
11.18 AccuGenomics
11.18.1 AccuGenomics Company Details
11.18.2 AccuGenomics Business Overview
11.18.3 AccuGenomics Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Introduction
11.18.4 AccuGenomics Revenue in Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Business (2020-2025)
11.18.5 AccuGenomics Recent Development
11.19 ACEA Biosciences
11.19.1 ACEA Biosciences Company Details
11.19.2 ACEA Biosciences Business Overview
11.19.3 ACEA Biosciences Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Introduction
11.19.4 ACEA Biosciences Revenue in Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Business (2020-2025)
11.19.5 ACEA Biosciences Recent Development
11.20 AC Immune
11.20.1 AC Immune Company Details
11.20.2 AC Immune Business Overview
11.20.3 AC Immune Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Introduction
11.20.4 AC Immune Revenue in Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Business (2020-2025)
11.20.5 AC Immune Recent Development
11.21 Acoustic MedSystems
11.21.1 Acoustic MedSystems Company Details
11.21.2 Acoustic MedSystems Business Overview
11.21.3 Acoustic MedSystems Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Introduction
11.21.4 Acoustic MedSystems Revenue in Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Business (2020-2025)
11.21.5 Acoustic MedSystems Recent Development
11.22 Adaptimmune
11.22.1 Adaptimmune Company Details
11.22.2 Adaptimmune Business Overview
11.22.3 Adaptimmune Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Introduction
11.22.4 Adaptimmune Revenue in Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Business (2020-2025)
11.22.5 Adaptimmune Recent Development
11.23 Aduro BioTech
11.23.1 Aduro BioTech Company Details
11.23.2 Aduro BioTech Business Overview
11.23.3 Aduro BioTech Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Introduction
11.23.4 Aduro BioTech Revenue in Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Business (2020-2025)
11.23.5 Aduro BioTech Recent Development
11.24 Advaxis
11.24.1 Advaxis Company Details
11.24.2 Advaxis Business Overview
11.24.3 Advaxis Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Introduction
11.24.4 Advaxis Revenue in Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Business (2020-2025)
11.24.5 Advaxis Recent Development
11.25 Adventus Ventures
11.25.1 Adventus Ventures Company Details
11.25.2 Adventus Ventures Business Overview
11.25.3 Adventus Ventures Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Introduction
11.25.4 Adventus Ventures Revenue in Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Business (2020-2025)
11.25.5 Adventus Ventures Recent Development
11.26 Aerolase
11.26.1 Aerolase Company Details
11.26.2 Aerolase Business Overview
11.26.3 Aerolase Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Introduction
11.26.4 Aerolase Revenue in Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Business (2020-2025)
11.26.5 Aerolase Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.1.1 Research Programs/Design
13.1.1.2 Market Size Estimation
13.1.1.3 Market Breakdown and Data Triangulation
13.1.2 Data Source
13.1.2.1 Secondary Sources
13.1.2.2 Primary Sources
13.2 Author Details
13.3 Disclaimer
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Market Size Growth Rate by Type: 2020 VS 2024 VS 2031
1.2.2 Asset purchase
1.2.3 Assignment
1.2.4 Co-development
1.2.5 Co-market
1.2.6 Co-promotion
1.2.7 Collaborative R&D
1.2.8 Contract service
1.2.9 CRADA
1.2.10 Cross-licensing
1.3 Market by Application
1.3.1 Global Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Market Growth by Application: 2020 VS 2024 VS 2031
1.3.2 Industry sector
1.3.3 Therapy areas
1.3.4 Technology type
1.3.5 Deal components
1.3.6 Financial terms
1.3.7 Stage of development
1.3.8 Others
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Global Growth Trends
2.1 Global Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Market Perspective (2020-2031)
2.2 Global Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Growth Trends by Region
2.2.1 Global Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Market Size by Region: 2020 VS 2024 VS 2031
2.2.2 Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Historic Market Size by Region (2020-2025)
2.2.3 Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Forecasted Market Size by Region (2026-2031)
2.3 Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Market Dynamics
2.3.1 Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Industry Trends
2.3.2 Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Market Drivers
2.3.3 Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Market Challenges
2.3.4 Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Players by Revenue
3.1.1 Global Top Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Players by Revenue (2020-2025)
3.1.2 Global Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Revenue Market Share by Players (2020-2025)
3.2 Global Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Global Key Players Ranking by Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Revenue
3.4 Global Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Market Concentration Ratio
3.4.1 Global Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Revenue in 2024
3.5 Global Key Players of Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Head office and Area Served
3.6 Global Key Players of Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics, Product and Application
3.7 Global Key Players of Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics, Date of Enter into This Industry
3.8 Mergers & Acquisitions, Expansion Plans
4 Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Breakdown Data by Type
4.1 Global Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Historic Market Size by Type (2020-2025)
4.2 Global Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Forecasted Market Size by Type (2026-2031)
5 Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Breakdown Data by Application
5.1 Global Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Historic Market Size by Application (2020-2025)
5.2 Global Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Forecasted Market Size by Application (2026-2031)
6 North America
6.1 North America Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Market Size (2020-2031)
6.2 North America Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Market Growth Rate by Country: 2020 VS 2024 VS 2031
6.3 North America Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Market Size by Country (2020-2025)
6.4 North America Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Market Size by Country (2026-2031)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Market Size (2020-2031)
7.2 Europe Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Market Growth Rate by Country: 2020 VS 2024 VS 2031
7.3 Europe Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Market Size by Country (2020-2025)
7.4 Europe Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Market Size by Country (2026-2031)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Market Size (2020-2031)
8.2 Asia-Pacific Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Market Growth Rate by Region: 2020 VS 2024 VS 2031
8.3 Asia-Pacific Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Market Size by Region (2020-2025)
8.4 Asia-Pacific Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Market Size by Region (2026-2031)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Market Size (2020-2031)
9.2 Latin America Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Market Growth Rate by Country: 2020 VS 2024 VS 2031
9.3 Latin America Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Market Size by Country (2020-2025)
9.4 Latin America Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Market Size by Country (2026-2031)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Market Size (2020-2031)
10.2 Middle East & Africa Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Market Growth Rate by Country: 2020 VS 2024 VS 2031
10.3 Middle East & Africa Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Market Size by Country (2020-2025)
10.4 Middle East & Africa Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Market Size by Country (2026-2031)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 1ST Biotherapeutics
11.1.1 1ST Biotherapeutics Company Details
11.1.2 1ST Biotherapeutics Business Overview
11.1.3 1ST Biotherapeutics Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Introduction
11.1.4 1ST Biotherapeutics Revenue in Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Business (2020-2025)
11.1.5 1ST Biotherapeutics Recent Development
11.2 3B Pharmaceuticals
11.2.1 3B Pharmaceuticals Company Details
11.2.2 3B Pharmaceuticals Business Overview
11.2.3 3B Pharmaceuticals Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Introduction
11.2.4 3B Pharmaceuticals Revenue in Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Business (2020-2025)
11.2.5 3B Pharmaceuticals Recent Development
11.3 3D-Micromac
11.3.1 3D-Micromac Company Details
11.3.2 3D-Micromac Business Overview
11.3.3 3D-Micromac Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Introduction
11.3.4 3D-Micromac Revenue in Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Business (2020-2025)
11.3.5 3D-Micromac Recent Development
11.4 3DMed
11.4.1 3DMed Company Details
11.4.2 3DMed Business Overview
11.4.3 3DMed Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Introduction
11.4.4 3DMed Revenue in Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Business (2020-2025)
11.4.5 3DMed Recent Development
11.5 3D Systems
11.5.1 3D Systems Company Details
11.5.2 3D Systems Business Overview
11.5.3 3D Systems Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Introduction
11.5.4 3D Systems Revenue in Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Business (2020-2025)
11.5.5 3D Systems Recent Development
11.6 10X Genomics
11.6.1 10X Genomics Company Details
11.6.2 10X Genomics Business Overview
11.6.3 10X Genomics Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Introduction
11.6.4 10X Genomics Revenue in Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Business (2020-2025)
11.6.5 10X Genomics Recent Development
11.7 A*STAR Agency for Science
11.7.1 A*STAR Agency for Science Company Details
11.7.2 A*STAR Agency for Science Business Overview
11.7.3 A*STAR Agency for Science Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Introduction
11.7.4 A*STAR Agency for Science Revenue in Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Business (2020-2025)
11.7.5 A*STAR Agency for Science Recent Development
11.8 Technology and Research
11.8.1 Technology and Research Company Details
11.8.2 Technology and Research Business Overview
11.8.3 Technology and Research Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Introduction
11.8.4 Technology and Research Revenue in Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Business (2020-2025)
11.8.5 Technology and Research Recent Development
11.9 A*STAR Institute of Microelectronics (IME)
11.9.1 A*STAR Institute of Microelectronics (IME) Company Details
11.9.2 A*STAR Institute of Microelectronics (IME) Business Overview
11.9.3 A*STAR Institute of Microelectronics (IME) Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Introduction
11.9.4 A*STAR Institute of Microelectronics (IME) Revenue in Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Business (2020-2025)
11.9.5 A*STAR Institute of Microelectronics (IME) Recent Development
11.10 A2A Pharmaceuticals
11.10.1 A2A Pharmaceuticals Company Details
11.10.2 A2A Pharmaceuticals Business Overview
11.10.3 A2A Pharmaceuticals Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Introduction
11.10.4 A2A Pharmaceuticals Revenue in Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Business (2020-2025)
11.10.5 A2A Pharmaceuticals Recent Development
11.11 Abbvie
11.11.1 Abbvie Company Details
11.11.2 Abbvie Business Overview
11.11.3 Abbvie Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Introduction
11.11.4 Abbvie Revenue in Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Business (2020-2025)
11.11.5 Abbvie Recent Development
11.12 AbCellera
11.12.1 AbCellera Company Details
11.12.2 AbCellera Business Overview
11.12.3 AbCellera Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Introduction
11.12.4 AbCellera Revenue in Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Business (2020-2025)
11.12.5 AbCellera Recent Development
11.13 ABL Bio
11.13.1 ABL Bio Company Details
11.13.2 ABL Bio Business Overview
11.13.3 ABL Bio Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Introduction
11.13.4 ABL Bio Revenue in Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Business (2020-2025)
11.13.5 ABL Bio Recent Development
11.14 Abpro
11.14.1 Abpro Company Details
11.14.2 Abpro Business Overview
11.14.3 Abpro Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Introduction
11.14.4 Abpro Revenue in Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Business (2020-2025)
11.14.5 Abpro Recent Development
11.15 Academy of Military Medical Sciences (China)
11.15.1 Academy of Military Medical Sciences (China) Company Details
11.15.2 Academy of Military Medical Sciences (China) Business Overview
11.15.3 Academy of Military Medical Sciences (China) Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Introduction
11.15.4 Academy of Military Medical Sciences (China) Revenue in Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Business (2020-2025)
11.15.5 Academy of Military Medical Sciences (China) Recent Development
11.16 Accellix
11.16.1 Accellix Company Details
11.16.2 Accellix Business Overview
11.16.3 Accellix Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Introduction
11.16.4 Accellix Revenue in Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Business (2020-2025)
11.16.5 Accellix Recent Development
11.17 Accord Healthcare
11.17.1 Accord Healthcare Company Details
11.17.2 Accord Healthcare Business Overview
11.17.3 Accord Healthcare Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Introduction
11.17.4 Accord Healthcare Revenue in Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Business (2020-2025)
11.17.5 Accord Healthcare Recent Development
11.18 AccuGenomics
11.18.1 AccuGenomics Company Details
11.18.2 AccuGenomics Business Overview
11.18.3 AccuGenomics Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Introduction
11.18.4 AccuGenomics Revenue in Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Business (2020-2025)
11.18.5 AccuGenomics Recent Development
11.19 ACEA Biosciences
11.19.1 ACEA Biosciences Company Details
11.19.2 ACEA Biosciences Business Overview
11.19.3 ACEA Biosciences Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Introduction
11.19.4 ACEA Biosciences Revenue in Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Business (2020-2025)
11.19.5 ACEA Biosciences Recent Development
11.20 AC Immune
11.20.1 AC Immune Company Details
11.20.2 AC Immune Business Overview
11.20.3 AC Immune Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Introduction
11.20.4 AC Immune Revenue in Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Business (2020-2025)
11.20.5 AC Immune Recent Development
11.21 Acoustic MedSystems
11.21.1 Acoustic MedSystems Company Details
11.21.2 Acoustic MedSystems Business Overview
11.21.3 Acoustic MedSystems Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Introduction
11.21.4 Acoustic MedSystems Revenue in Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Business (2020-2025)
11.21.5 Acoustic MedSystems Recent Development
11.22 Adaptimmune
11.22.1 Adaptimmune Company Details
11.22.2 Adaptimmune Business Overview
11.22.3 Adaptimmune Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Introduction
11.22.4 Adaptimmune Revenue in Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Business (2020-2025)
11.22.5 Adaptimmune Recent Development
11.23 Aduro BioTech
11.23.1 Aduro BioTech Company Details
11.23.2 Aduro BioTech Business Overview
11.23.3 Aduro BioTech Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Introduction
11.23.4 Aduro BioTech Revenue in Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Business (2020-2025)
11.23.5 Aduro BioTech Recent Development
11.24 Advaxis
11.24.1 Advaxis Company Details
11.24.2 Advaxis Business Overview
11.24.3 Advaxis Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Introduction
11.24.4 Advaxis Revenue in Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Business (2020-2025)
11.24.5 Advaxis Recent Development
11.25 Adventus Ventures
11.25.1 Adventus Ventures Company Details
11.25.2 Adventus Ventures Business Overview
11.25.3 Adventus Ventures Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Introduction
11.25.4 Adventus Ventures Revenue in Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Business (2020-2025)
11.25.5 Adventus Ventures Recent Development
11.26 Aerolase
11.26.1 Aerolase Company Details
11.26.2 Aerolase Business Overview
11.26.3 Aerolase Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Introduction
11.26.4 Aerolase Revenue in Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Business (2020-2025)
11.26.5 Aerolase Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.1.1 Research Programs/Design
13.1.1.2 Market Size Estimation
13.1.1.3 Market Breakdown and Data Triangulation
13.1.2 Data Source
13.1.2.1 Secondary Sources
13.1.2.2 Primary Sources
13.2 Author Details
13.3 Disclaimer
List of Tables
Table 1. Global Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Market Size Growth Rate by Type (US$ Million): 2020 VS 2024 VS 2031
Table 2. Key Players of Asset purchase
Table 3. Key Players of Assignment
Table 4. Key Players of Co-development
Table 5. Key Players of Co-market
Table 6. Key Players of Co-promotion
Table 7. Key Players of Collaborative R&D
Table 8. Key Players of Contract service
Table 9. Global Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Market Size Growth by Application (US$ Million): 2020 VS 2024 VS 2031
Table 10. Global Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Market Size by Region (US$ Million): 2020 VS 2024 VS 2031
Table 11. Global Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Market Size by Region (2020-2025) & (US$ Million)
Table 12. Global Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Market Share by Region (2020-2025)
Table 13. Global Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Forecasted Market Size by Region (2026-2031) & (US$ Million)
Table 14. Global Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Market Share by Region (2026-2031)
Table 15. Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Market Trends
Table 16. Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Market Drivers
Table 17. Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Market Challenges
Table 18. Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Market Restraints
Table 19. Global Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Revenue by Players (2020-2025) & (US$ Million)
Table 20. Global Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Market Share by Players (2020-2025)
Table 21. Global Top Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics as of 2024)
Table 22. Ranking of Global Top Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Companies by Revenue (US$ Million) in 2024
Table 23. Global 5 Largest Players Market Share by Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Revenue (CR5 and HHI) & (2020-2025)
Table 24. Global Key Players of Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics, Headquarters and Area Served
Table 25. Global Key Players of Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics, Product and Application
Table 26. Global Key Players of Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics, Date of Enter into This Industry
Table 27. Mergers & Acquisitions, Expansion Plans
Table 28. Global Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Market Size by Type (2020-2025) & (US$ Million)
Table 29. Global Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Revenue Market Share by Type (2020-2025)
Table 30. Global Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Forecasted Market Size by Type (2026-2031) & (US$ Million)
Table 31. Global Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Revenue Market Share by Type (2026-2031)
Table 32. Global Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Market Size by Application (2020-2025) & (US$ Million)
Table 33. Global Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Revenue Market Share by Application (2020-2025)
Table 34. Global Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Forecasted Market Size by Application (2026-2031) & (US$ Million)
Table 35. Global Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Revenue Market Share by Application (2026-2031)
Table 36. North America Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 37. North America Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Market Size by Country (2020-2025) & (US$ Million)
Table 38. North America Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Market Size by Country (2026-2031) & (US$ Million)
Table 39. Europe Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 40. Europe Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Market Size by Country (2020-2025) & (US$ Million)
Table 41. Europe Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Market Size by Country (2026-2031) & (US$ Million)
Table 42. Asia-Pacific Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Market Size Growth Rate by Region (US$ Million): 2020 VS 2024 VS 2031
Table 43. Asia-Pacific Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Market Size by Region (2020-2025) & (US$ Million)
Table 44. Asia-Pacific Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Market Size by Region (2026-2031) & (US$ Million)
Table 45. Latin America Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 46. Latin America Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Market Size by Country (2020-2025) & (US$ Million)
Table 47. Latin America Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Market Size by Country (2026-2031) & (US$ Million)
Table 48. Middle East & Africa Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 49. Middle East & Africa Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Market Size by Country (2020-2025) & (US$ Million)
Table 50. Middle East & Africa Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Market Size by Country (2026-2031) & (US$ Million)
Table 51. 1ST Biotherapeutics Company Details
Table 52. 1ST Biotherapeutics Business Overview
Table 53. 1ST Biotherapeutics Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Product
Table 54. 1ST Biotherapeutics Revenue in Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Business (2020-2025) & (US$ Million)
Table 55. 1ST Biotherapeutics Recent Development
Table 56. 3B Pharmaceuticals Company Details
Table 57. 3B Pharmaceuticals Business Overview
Table 58. 3B Pharmaceuticals Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Product
Table 59. 3B Pharmaceuticals Revenue in Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Business (2020-2025) & (US$ Million)
Table 60. 3B Pharmaceuticals Recent Development
Table 61. 3D-Micromac Company Details
Table 62. 3D-Micromac Business Overview
Table 63. 3D-Micromac Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Product
Table 64. 3D-Micromac Revenue in Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Business (2020-2025) & (US$ Million)
Table 65. 3D-Micromac Recent Development
Table 66. 3DMed Company Details
Table 67. 3DMed Business Overview
Table 68. 3DMed Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Product
Table 69. 3DMed Revenue in Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Business (2020-2025) & (US$ Million)
Table 70. 3DMed Recent Development
Table 71. 3D Systems Company Details
Table 72. 3D Systems Business Overview
Table 73. 3D Systems Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Product
Table 74. 3D Systems Revenue in Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Business (2020-2025) & (US$ Million)
Table 75. 3D Systems Recent Development
Table 76. 10X Genomics Company Details
Table 77. 10X Genomics Business Overview
Table 78. 10X Genomics Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Product
Table 79. 10X Genomics Revenue in Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Business (2020-2025) & (US$ Million)
Table 80. 10X Genomics Recent Development
Table 81. A*STAR Agency for Science Company Details
Table 82. A*STAR Agency for Science Business Overview
Table 83. A*STAR Agency for Science Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Product
Table 84. A*STAR Agency for Science Revenue in Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Business (2020-2025) & (US$ Million)
Table 85. A*STAR Agency for Science Recent Development
Table 86. Technology and Research Company Details
Table 87. Technology and Research Business Overview
Table 88. Technology and Research Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Product
Table 89. Technology and Research Revenue in Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Business (2020-2025) & (US$ Million)
Table 90. Technology and Research Recent Development
Table 91. A*STAR Institute of Microelectronics (IME) Company Details
Table 92. A*STAR Institute of Microelectronics (IME) Business Overview
Table 93. A*STAR Institute of Microelectronics (IME) Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Product
Table 94. A*STAR Institute of Microelectronics (IME) Revenue in Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Business (2020-2025) & (US$ Million)
Table 95. A*STAR Institute of Microelectronics (IME) Recent Development
Table 96. A2A Pharmaceuticals Company Details
Table 97. A2A Pharmaceuticals Business Overview
Table 98. A2A Pharmaceuticals Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Product
Table 99. A2A Pharmaceuticals Revenue in Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Business (2020-2025) & (US$ Million)
Table 100. A2A Pharmaceuticals Recent Development
Table 101. Abbvie Company Details
Table 102. Abbvie Business Overview
Table 103. Abbvie Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Product
Table 104. Abbvie Revenue in Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Business (2020-2025) & (US$ Million)
Table 105. Abbvie Recent Development
Table 106. AbCellera Company Details
Table 107. AbCellera Business Overview
Table 108. AbCellera Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Product
Table 109. AbCellera Revenue in Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Business (2020-2025) & (US$ Million)
Table 110. AbCellera Recent Development
Table 111. ABL Bio Company Details
Table 112. ABL Bio Business Overview
Table 113. ABL Bio Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Product
Table 114. ABL Bio Revenue in Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Business (2020-2025) & (US$ Million)
Table 115. ABL Bio Recent Development
Table 116. Abpro Company Details
Table 117. Abpro Business Overview
Table 118. Abpro Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Product
Table 119. Abpro Revenue in Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Business (2020-2025) & (US$ Million)
Table 120. Abpro Recent Development
Table 121. Academy of Military Medical Sciences (China) Company Details
Table 122. Academy of Military Medical Sciences (China) Business Overview
Table 123. Academy of Military Medical Sciences (China) Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Product
Table 124. Academy of Military Medical Sciences (China) Revenue in Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Business (2020-2025) & (US$ Million)
Table 125. Academy of Military Medical Sciences (China) Recent Development
Table 126. Accellix Company Details
Table 127. Accellix Business Overview
Table 128. Accellix Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Product
Table 129. Accellix Revenue in Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Business (2020-2025) & (US$ Million)
Table 130. Accellix Recent Development
Table 131. Accord Healthcare Company Details
Table 132. Accord Healthcare Business Overview
Table 133. Accord Healthcare Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Product
Table 134. Accord Healthcare Revenue in Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Business (2020-2025) & (US$ Million)
Table 135. Accord Healthcare Recent Development
Table 136. AccuGenomics Company Details
Table 137. AccuGenomics Business Overview
Table 138. AccuGenomics Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Product
Table 139. AccuGenomics Revenue in Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Business (2020-2025) & (US$ Million)
Table 140. AccuGenomics Recent Development
Table 141. ACEA Biosciences Company Details
Table 142. ACEA Biosciences Business Overview
Table 143. ACEA Biosciences Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Product
Table 144. ACEA Biosciences Revenue in Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Business (2020-2025) & (US$ Million)
Table 145. ACEA Biosciences Recent Development
Table 146. AC Immune Company Details
Table 147. AC Immune Business Overview
Table 148. AC Immune Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Product
Table 149. AC Immune Revenue in Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Business (2020-2025) & (US$ Million)
Table 150. AC Immune Recent Development
Table 151. Acoustic MedSystems Company Details
Table 152. Acoustic MedSystems Business Overview
Table 153. Acoustic MedSystems Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Product
Table 154. Acoustic MedSystems Revenue in Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Business (2020-2025) & (US$ Million)
Table 155. Acoustic MedSystems Recent Development
Table 156. Adaptimmune Company Details
Table 157. Adaptimmune Business Overview
Table 158. Adaptimmune Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Product
Table 159. Adaptimmune Revenue in Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Business (2020-2025) & (US$ Million)
Table 160. Adaptimmune Recent Development
Table 161. Aduro BioTech Company Details
Table 162. Aduro BioTech Business Overview
Table 163. Aduro BioTech Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Product
Table 164. Aduro BioTech Revenue in Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Business (2020-2025) & (US$ Million)
Table 165. Aduro BioTech Recent Development
Table 166. Advaxis Company Details
Table 167. Advaxis Business Overview
Table 168. Advaxis Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Product
Table 169. Advaxis Revenue in Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Business (2020-2025) & (US$ Million)
Table 170. Advaxis Recent Development
Table 171. Adventus Ventures Company Details
Table 172. Adventus Ventures Business Overview
Table 173. Adventus Ventures Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Product
Table 174. Adventus Ventures Revenue in Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Business (2020-2025) & (US$ Million)
Table 175. Adventus Ventures Recent Development
Table 176. Aerolase Company Details
Table 177. Aerolase Business Overview
Table 178. Aerolase Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Product
Table 179. Aerolase Revenue in Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Business (2020-2025) & (US$ Million)
Table 180. Aerolase Recent Development
Table 181. Research Programs/Design for This Report
Table 182. Key Data Information from Secondary Sources
Table 183. Key Data Information from Primary Sources
Table 184. Authors List of This Report
List of Figures
Figure 1. Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Picture
Figure 2. Global Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Market Size Comparison by Type (2020-2031) & (US$ Million)
Figure 3. Global Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Market Share by Type: 2024 VS 2031
Figure 4. Asset purchase Features
Figure 5. Assignment Features
Figure 6. Co-development Features
Figure 7. Co-market Features
Figure 8. Co-promotion Features
Figure 9. Collaborative R&D Features
Figure 10. Contract service Features
Figure 11. CRADA Features
Figure 12. Cross-licensing Features
Figure 13. Global Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Market Size by Application (2020-2031) & (US$ Million)
Figure 14. Global Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Market Share by Application: 2024 VS 2031
Figure 15. Industry sector Case Studies
Figure 16. Therapy areas Case Studies
Figure 17. Technology type Case Studies
Figure 18. Deal components Case Studies
Figure 19. Financial terms Case Studies
Figure 20. Stage of development Case Studies
Figure 21. Others Case Studies
Figure 22. Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Report Years Considered
Figure 23. Global Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Market Size (US$ Million), Year-over-Year: 2020-2031
Figure 24. Global Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Market Size, (US$ Million), 2020 VS 2024 VS 2031
Figure 25. Global Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Market Share by Region: 2024 VS 2031
Figure 26. Global Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Market Share by Players in 2024
Figure 27. Global Top Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics as of 2024)
Figure 28. The Top 10 and 5 Players Market Share by Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Revenue in 2024
Figure 29. North America Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 30. North America Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Market Share by Country (2020-2031)
Figure 31. United States Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 32. Canada Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 33. Europe Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 34. Europe Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Market Share by Country (2020-2031)
Figure 35. Germany Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 36. France Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 37. U.K. Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 38. Italy Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 39. Russia Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 40. Nordic Countries Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 41. Asia-Pacific Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 42. Asia-Pacific Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Market Share by Region (2020-2031)
Figure 43. China Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 44. Japan Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 45. South Korea Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 46. Southeast Asia Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 47. India Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 48. Australia Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 49. Latin America Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 50. Latin America Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Market Share by Country (2020-2031)
Figure 51. Mexico Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 52. Brazil Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 53. Middle East & Africa Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 54. Middle East & Africa Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Market Share by Country (2020-2031)
Figure 55. Turkey Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 56. Saudi Arabia Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 57. UAE Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 58. 1ST Biotherapeutics Revenue Growth Rate in Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Business (2020-2025)
Figure 59. 3B Pharmaceuticals Revenue Growth Rate in Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Business (2020-2025)
Figure 60. 3D-Micromac Revenue Growth Rate in Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Business (2020-2025)
Figure 61. 3DMed Revenue Growth Rate in Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Business (2020-2025)
Figure 62. 3D Systems Revenue Growth Rate in Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Business (2020-2025)
Figure 63. 10X Genomics Revenue Growth Rate in Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Business (2020-2025)
Figure 64. A*STAR Agency for Science Revenue Growth Rate in Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Business (2020-2025)
Figure 65. Technology and Research Revenue Growth Rate in Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Business (2020-2025)
Figure 66. A*STAR Institute of Microelectronics (IME) Revenue Growth Rate in Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Business (2020-2025)
Figure 67. A2A Pharmaceuticals Revenue Growth Rate in Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Business (2020-2025)
Figure 68. Abbvie Revenue Growth Rate in Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Business (2020-2025)
Figure 69. AbCellera Revenue Growth Rate in Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Business (2020-2025)
Figure 70. ABL Bio Revenue Growth Rate in Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Business (2020-2025)
Figure 71. Abpro Revenue Growth Rate in Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Business (2020-2025)
Figure 72. Academy of Military Medical Sciences (China) Revenue Growth Rate in Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Business (2020-2025)
Figure 73. Accellix Revenue Growth Rate in Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Business (2020-2025)
Figure 74. Accord Healthcare Revenue Growth Rate in Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Business (2020-2025)
Figure 75. AccuGenomics Revenue Growth Rate in Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Business (2020-2025)
Figure 76. ACEA Biosciences Revenue Growth Rate in Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Business (2020-2025)
Figure 77. AC Immune Revenue Growth Rate in Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Business (2020-2025)
Figure 78. Acoustic MedSystems Revenue Growth Rate in Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Business (2020-2025)
Figure 79. Adaptimmune Revenue Growth Rate in Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Business (2020-2025)
Figure 80. Aduro BioTech Revenue Growth Rate in Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Business (2020-2025)
Figure 81. Advaxis Revenue Growth Rate in Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Business (2020-2025)
Figure 82. Adventus Ventures Revenue Growth Rate in Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Business (2020-2025)
Figure 83. Aerolase Revenue Growth Rate in Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Business (2020-2025)
Figure 84. Bottom-up and Top-down Approaches for This Report
Figure 85. Data Triangulation
Figure 86. Key Executives Interviewed
Table 1. Global Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Market Size Growth Rate by Type (US$ Million): 2020 VS 2024 VS 2031
Table 2. Key Players of Asset purchase
Table 3. Key Players of Assignment
Table 4. Key Players of Co-development
Table 5. Key Players of Co-market
Table 6. Key Players of Co-promotion
Table 7. Key Players of Collaborative R&D
Table 8. Key Players of Contract service
Table 9. Global Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Market Size Growth by Application (US$ Million): 2020 VS 2024 VS 2031
Table 10. Global Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Market Size by Region (US$ Million): 2020 VS 2024 VS 2031
Table 11. Global Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Market Size by Region (2020-2025) & (US$ Million)
Table 12. Global Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Market Share by Region (2020-2025)
Table 13. Global Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Forecasted Market Size by Region (2026-2031) & (US$ Million)
Table 14. Global Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Market Share by Region (2026-2031)
Table 15. Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Market Trends
Table 16. Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Market Drivers
Table 17. Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Market Challenges
Table 18. Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Market Restraints
Table 19. Global Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Revenue by Players (2020-2025) & (US$ Million)
Table 20. Global Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Market Share by Players (2020-2025)
Table 21. Global Top Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics as of 2024)
Table 22. Ranking of Global Top Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Companies by Revenue (US$ Million) in 2024
Table 23. Global 5 Largest Players Market Share by Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Revenue (CR5 and HHI) & (2020-2025)
Table 24. Global Key Players of Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics, Headquarters and Area Served
Table 25. Global Key Players of Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics, Product and Application
Table 26. Global Key Players of Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics, Date of Enter into This Industry
Table 27. Mergers & Acquisitions, Expansion Plans
Table 28. Global Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Market Size by Type (2020-2025) & (US$ Million)
Table 29. Global Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Revenue Market Share by Type (2020-2025)
Table 30. Global Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Forecasted Market Size by Type (2026-2031) & (US$ Million)
Table 31. Global Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Revenue Market Share by Type (2026-2031)
Table 32. Global Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Market Size by Application (2020-2025) & (US$ Million)
Table 33. Global Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Revenue Market Share by Application (2020-2025)
Table 34. Global Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Forecasted Market Size by Application (2026-2031) & (US$ Million)
Table 35. Global Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Revenue Market Share by Application (2026-2031)
Table 36. North America Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 37. North America Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Market Size by Country (2020-2025) & (US$ Million)
Table 38. North America Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Market Size by Country (2026-2031) & (US$ Million)
Table 39. Europe Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 40. Europe Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Market Size by Country (2020-2025) & (US$ Million)
Table 41. Europe Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Market Size by Country (2026-2031) & (US$ Million)
Table 42. Asia-Pacific Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Market Size Growth Rate by Region (US$ Million): 2020 VS 2024 VS 2031
Table 43. Asia-Pacific Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Market Size by Region (2020-2025) & (US$ Million)
Table 44. Asia-Pacific Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Market Size by Region (2026-2031) & (US$ Million)
Table 45. Latin America Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 46. Latin America Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Market Size by Country (2020-2025) & (US$ Million)
Table 47. Latin America Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Market Size by Country (2026-2031) & (US$ Million)
Table 48. Middle East & Africa Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 49. Middle East & Africa Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Market Size by Country (2020-2025) & (US$ Million)
Table 50. Middle East & Africa Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Market Size by Country (2026-2031) & (US$ Million)
Table 51. 1ST Biotherapeutics Company Details
Table 52. 1ST Biotherapeutics Business Overview
Table 53. 1ST Biotherapeutics Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Product
Table 54. 1ST Biotherapeutics Revenue in Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Business (2020-2025) & (US$ Million)
Table 55. 1ST Biotherapeutics Recent Development
Table 56. 3B Pharmaceuticals Company Details
Table 57. 3B Pharmaceuticals Business Overview
Table 58. 3B Pharmaceuticals Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Product
Table 59. 3B Pharmaceuticals Revenue in Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Business (2020-2025) & (US$ Million)
Table 60. 3B Pharmaceuticals Recent Development
Table 61. 3D-Micromac Company Details
Table 62. 3D-Micromac Business Overview
Table 63. 3D-Micromac Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Product
Table 64. 3D-Micromac Revenue in Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Business (2020-2025) & (US$ Million)
Table 65. 3D-Micromac Recent Development
Table 66. 3DMed Company Details
Table 67. 3DMed Business Overview
Table 68. 3DMed Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Product
Table 69. 3DMed Revenue in Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Business (2020-2025) & (US$ Million)
Table 70. 3DMed Recent Development
Table 71. 3D Systems Company Details
Table 72. 3D Systems Business Overview
Table 73. 3D Systems Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Product
Table 74. 3D Systems Revenue in Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Business (2020-2025) & (US$ Million)
Table 75. 3D Systems Recent Development
Table 76. 10X Genomics Company Details
Table 77. 10X Genomics Business Overview
Table 78. 10X Genomics Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Product
Table 79. 10X Genomics Revenue in Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Business (2020-2025) & (US$ Million)
Table 80. 10X Genomics Recent Development
Table 81. A*STAR Agency for Science Company Details
Table 82. A*STAR Agency for Science Business Overview
Table 83. A*STAR Agency for Science Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Product
Table 84. A*STAR Agency for Science Revenue in Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Business (2020-2025) & (US$ Million)
Table 85. A*STAR Agency for Science Recent Development
Table 86. Technology and Research Company Details
Table 87. Technology and Research Business Overview
Table 88. Technology and Research Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Product
Table 89. Technology and Research Revenue in Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Business (2020-2025) & (US$ Million)
Table 90. Technology and Research Recent Development
Table 91. A*STAR Institute of Microelectronics (IME) Company Details
Table 92. A*STAR Institute of Microelectronics (IME) Business Overview
Table 93. A*STAR Institute of Microelectronics (IME) Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Product
Table 94. A*STAR Institute of Microelectronics (IME) Revenue in Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Business (2020-2025) & (US$ Million)
Table 95. A*STAR Institute of Microelectronics (IME) Recent Development
Table 96. A2A Pharmaceuticals Company Details
Table 97. A2A Pharmaceuticals Business Overview
Table 98. A2A Pharmaceuticals Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Product
Table 99. A2A Pharmaceuticals Revenue in Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Business (2020-2025) & (US$ Million)
Table 100. A2A Pharmaceuticals Recent Development
Table 101. Abbvie Company Details
Table 102. Abbvie Business Overview
Table 103. Abbvie Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Product
Table 104. Abbvie Revenue in Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Business (2020-2025) & (US$ Million)
Table 105. Abbvie Recent Development
Table 106. AbCellera Company Details
Table 107. AbCellera Business Overview
Table 108. AbCellera Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Product
Table 109. AbCellera Revenue in Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Business (2020-2025) & (US$ Million)
Table 110. AbCellera Recent Development
Table 111. ABL Bio Company Details
Table 112. ABL Bio Business Overview
Table 113. ABL Bio Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Product
Table 114. ABL Bio Revenue in Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Business (2020-2025) & (US$ Million)
Table 115. ABL Bio Recent Development
Table 116. Abpro Company Details
Table 117. Abpro Business Overview
Table 118. Abpro Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Product
Table 119. Abpro Revenue in Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Business (2020-2025) & (US$ Million)
Table 120. Abpro Recent Development
Table 121. Academy of Military Medical Sciences (China) Company Details
Table 122. Academy of Military Medical Sciences (China) Business Overview
Table 123. Academy of Military Medical Sciences (China) Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Product
Table 124. Academy of Military Medical Sciences (China) Revenue in Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Business (2020-2025) & (US$ Million)
Table 125. Academy of Military Medical Sciences (China) Recent Development
Table 126. Accellix Company Details
Table 127. Accellix Business Overview
Table 128. Accellix Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Product
Table 129. Accellix Revenue in Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Business (2020-2025) & (US$ Million)
Table 130. Accellix Recent Development
Table 131. Accord Healthcare Company Details
Table 132. Accord Healthcare Business Overview
Table 133. Accord Healthcare Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Product
Table 134. Accord Healthcare Revenue in Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Business (2020-2025) & (US$ Million)
Table 135. Accord Healthcare Recent Development
Table 136. AccuGenomics Company Details
Table 137. AccuGenomics Business Overview
Table 138. AccuGenomics Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Product
Table 139. AccuGenomics Revenue in Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Business (2020-2025) & (US$ Million)
Table 140. AccuGenomics Recent Development
Table 141. ACEA Biosciences Company Details
Table 142. ACEA Biosciences Business Overview
Table 143. ACEA Biosciences Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Product
Table 144. ACEA Biosciences Revenue in Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Business (2020-2025) & (US$ Million)
Table 145. ACEA Biosciences Recent Development
Table 146. AC Immune Company Details
Table 147. AC Immune Business Overview
Table 148. AC Immune Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Product
Table 149. AC Immune Revenue in Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Business (2020-2025) & (US$ Million)
Table 150. AC Immune Recent Development
Table 151. Acoustic MedSystems Company Details
Table 152. Acoustic MedSystems Business Overview
Table 153. Acoustic MedSystems Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Product
Table 154. Acoustic MedSystems Revenue in Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Business (2020-2025) & (US$ Million)
Table 155. Acoustic MedSystems Recent Development
Table 156. Adaptimmune Company Details
Table 157. Adaptimmune Business Overview
Table 158. Adaptimmune Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Product
Table 159. Adaptimmune Revenue in Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Business (2020-2025) & (US$ Million)
Table 160. Adaptimmune Recent Development
Table 161. Aduro BioTech Company Details
Table 162. Aduro BioTech Business Overview
Table 163. Aduro BioTech Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Product
Table 164. Aduro BioTech Revenue in Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Business (2020-2025) & (US$ Million)
Table 165. Aduro BioTech Recent Development
Table 166. Advaxis Company Details
Table 167. Advaxis Business Overview
Table 168. Advaxis Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Product
Table 169. Advaxis Revenue in Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Business (2020-2025) & (US$ Million)
Table 170. Advaxis Recent Development
Table 171. Adventus Ventures Company Details
Table 172. Adventus Ventures Business Overview
Table 173. Adventus Ventures Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Product
Table 174. Adventus Ventures Revenue in Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Business (2020-2025) & (US$ Million)
Table 175. Adventus Ventures Recent Development
Table 176. Aerolase Company Details
Table 177. Aerolase Business Overview
Table 178. Aerolase Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Product
Table 179. Aerolase Revenue in Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Business (2020-2025) & (US$ Million)
Table 180. Aerolase Recent Development
Table 181. Research Programs/Design for This Report
Table 182. Key Data Information from Secondary Sources
Table 183. Key Data Information from Primary Sources
Table 184. Authors List of This Report
List of Figures
Figure 1. Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Picture
Figure 2. Global Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Market Size Comparison by Type (2020-2031) & (US$ Million)
Figure 3. Global Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Market Share by Type: 2024 VS 2031
Figure 4. Asset purchase Features
Figure 5. Assignment Features
Figure 6. Co-development Features
Figure 7. Co-market Features
Figure 8. Co-promotion Features
Figure 9. Collaborative R&D Features
Figure 10. Contract service Features
Figure 11. CRADA Features
Figure 12. Cross-licensing Features
Figure 13. Global Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Market Size by Application (2020-2031) & (US$ Million)
Figure 14. Global Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Market Share by Application: 2024 VS 2031
Figure 15. Industry sector Case Studies
Figure 16. Therapy areas Case Studies
Figure 17. Technology type Case Studies
Figure 18. Deal components Case Studies
Figure 19. Financial terms Case Studies
Figure 20. Stage of development Case Studies
Figure 21. Others Case Studies
Figure 22. Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Report Years Considered
Figure 23. Global Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Market Size (US$ Million), Year-over-Year: 2020-2031
Figure 24. Global Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Market Size, (US$ Million), 2020 VS 2024 VS 2031
Figure 25. Global Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Market Share by Region: 2024 VS 2031
Figure 26. Global Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Market Share by Players in 2024
Figure 27. Global Top Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics as of 2024)
Figure 28. The Top 10 and 5 Players Market Share by Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Revenue in 2024
Figure 29. North America Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 30. North America Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Market Share by Country (2020-2031)
Figure 31. United States Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 32. Canada Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 33. Europe Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 34. Europe Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Market Share by Country (2020-2031)
Figure 35. Germany Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 36. France Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 37. U.K. Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 38. Italy Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 39. Russia Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 40. Nordic Countries Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 41. Asia-Pacific Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 42. Asia-Pacific Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Market Share by Region (2020-2031)
Figure 43. China Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 44. Japan Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 45. South Korea Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 46. Southeast Asia Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 47. India Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 48. Australia Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 49. Latin America Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 50. Latin America Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Market Share by Country (2020-2031)
Figure 51. Mexico Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 52. Brazil Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 53. Middle East & Africa Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 54. Middle East & Africa Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Market Share by Country (2020-2031)
Figure 55. Turkey Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 56. Saudi Arabia Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 57. UAE Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 58. 1ST Biotherapeutics Revenue Growth Rate in Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Business (2020-2025)
Figure 59. 3B Pharmaceuticals Revenue Growth Rate in Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Business (2020-2025)
Figure 60. 3D-Micromac Revenue Growth Rate in Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Business (2020-2025)
Figure 61. 3DMed Revenue Growth Rate in Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Business (2020-2025)
Figure 62. 3D Systems Revenue Growth Rate in Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Business (2020-2025)
Figure 63. 10X Genomics Revenue Growth Rate in Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Business (2020-2025)
Figure 64. A*STAR Agency for Science Revenue Growth Rate in Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Business (2020-2025)
Figure 65. Technology and Research Revenue Growth Rate in Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Business (2020-2025)
Figure 66. A*STAR Institute of Microelectronics (IME) Revenue Growth Rate in Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Business (2020-2025)
Figure 67. A2A Pharmaceuticals Revenue Growth Rate in Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Business (2020-2025)
Figure 68. Abbvie Revenue Growth Rate in Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Business (2020-2025)
Figure 69. AbCellera Revenue Growth Rate in Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Business (2020-2025)
Figure 70. ABL Bio Revenue Growth Rate in Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Business (2020-2025)
Figure 71. Abpro Revenue Growth Rate in Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Business (2020-2025)
Figure 72. Academy of Military Medical Sciences (China) Revenue Growth Rate in Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Business (2020-2025)
Figure 73. Accellix Revenue Growth Rate in Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Business (2020-2025)
Figure 74. Accord Healthcare Revenue Growth Rate in Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Business (2020-2025)
Figure 75. AccuGenomics Revenue Growth Rate in Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Business (2020-2025)
Figure 76. ACEA Biosciences Revenue Growth Rate in Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Business (2020-2025)
Figure 77. AC Immune Revenue Growth Rate in Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Business (2020-2025)
Figure 78. Acoustic MedSystems Revenue Growth Rate in Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Business (2020-2025)
Figure 79. Adaptimmune Revenue Growth Rate in Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Business (2020-2025)
Figure 80. Aduro BioTech Revenue Growth Rate in Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Business (2020-2025)
Figure 81. Advaxis Revenue Growth Rate in Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Business (2020-2025)
Figure 82. Adventus Ventures Revenue Growth Rate in Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Business (2020-2025)
Figure 83. Aerolase Revenue Growth Rate in Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics Business (2020-2025)
Figure 84. Bottom-up and Top-down Approaches for This Report
Figure 85. Data Triangulation
Figure 86. Key Executives Interviewed
Our team would be happy to assist you with your queries.
About us
Accurate data, The latest market trends, And deeper research directions.
Our sole purpose is to provide a basis for leaders in all walks of life to make more appropriate decisions, to help companies solve existing problems and achieve business goals
Latest reports
Global Electrolytes for Lithium-Ion Batteries Market Research Report 2025
Jul 14, 25
Global Vanadium Products Market Research Report 2025
Jul 14, 25
Global High-purity Vanadium Oxide Market Research Report 2025
Jul 14, 25
Useful links
Our Contacts
Room 2306, T6 Fuxing World Financial Center, Kaifu District, Changsha, Hunan, China
(+86) 159 1069 5232